The market size of the Global direct-to-consumer genetic testing market in the year 2021 is valued at 1.45 billion and is predicted to reach 7.08 billion by the year 2030 at an 19.51% CAGR during the forecast period.
Direct access testing, also known as direct-to-consumer (DTC) testing, enables clients to order laboratory tests directly from a laboratory without necessarily involving their healthcare provider. Direct-to-consumer genetic testing provides a person's genetic information without needing a doctor or health insurance company. Customers can send the business a DNA sample and get immediate results. Direct-to-consumer genetic testing, among other things, raises awareness of numerous genetic illnesses that aid in predicting one's health and offer information on standard features and ancestry. DTC genetic testing is quick to deliver findings confidently, inexpensively, and easy to use. Such scenarios will help the market expand beneficially. One of the main factors projected to fuel the growth of the direct-to-consumer (DTC) genetic testing market over the anticipated period is the rise in public awareness. The direct-to-consumer (DTC) genetic testing industry is also expected to grow due to the increase in income levels in developing nations. Additionally, the growing need for service personalization will likely create additional chances for the direct-to-consumer (DTC) genetic testing industry to expand over the next few years.
However, direct-to-consumer (DTC) genetic testing market expansion may be hindered in the near future by flaws in the DTC testing kits. Direct-to-consumer (DTC) genetic testing market expansion is anticipated to be hampered over the timeframe due to the rising cost of DTC genetic testing. Furthermore, insufficient data links a particular genetic mutation to a given illness or functionality. Genetic privacy may also be jeopardized if testing businesses utilize their clients' genetic data improperly or if the information is stolen.
The direct-to-consumer genetic testing market is categorized on the basis of product type, technology, and distribution channel. Based on product type, the market is differentiated as ancestry, health and wellness, and entertainment. Based on technology, the market is segmented as targeted analysis, single nucleotide polymorphisms (SNPs), and whole genome sequencing (WGS). Based on distribution channels, the market is segmented into online channels and over-the-counter channels.
Based on product type, the ancestry testing segment is accounted as a significant contributor to the direct-to-consumer genetic testing market.
The rising demand for heritage tests is responsible for the expansion of the market for ancestry testing. It is projected that easy access to direct-to-consumer genetic testing would spur market growth and customers' desire to get in touch with their living relatives around the globe. Additionally, the recent development of ancestry DTC tests fills the gap between ancestry-related and health-related genetic testing. The segmental expansion will be aided by the availability of such ancestral DTC testing in the upcoming years. Ancestry test sales are expected to rise in the future due to people's growing curiosity about their family history and ancestors. Additionally, the industry would be supported by the significant demand for saliva or cheek swab-based DNA test kits in developed nations like Europe and North America.
Single Nucleotide Polymorphisms (SNPs) segment witnessed growth at a rapid rate.
It is projected that segmental advancement in analyzing the genome sequence would speed up the widespread use of SNP chips. SNP chips identify several alterations in a single letter to improve test performance even more. SNP arrays are used by several direct-to-consumer genetic test vendors, like Color Genomics and Genetics, to investigate genetic codes at a particular resolution and find true knowledge about altered genes that may result in any prospective issues. Segmental manufacturing would increase as SNP chips were used more frequently for their precise and effective performance. Additionally, compared to short tandem repetitions, single nucleotide polymorphism chips have lower mutation rates (STRs). Thus, it can facilitate kinship testing, encouraging the market in the next coming years.
The North American direct-to-consumer genetic testing market holds a significant revenue share in the region.
In the forecast period, North America to hold a major global market share. The high prevalence of rare illnesses, the presence of numerous disease registries, a sizable number of R&D centres for ultra-rare diseases, and significant investments in disease detection are all factors that contribute to the region's considerable market share. Customers with a lot of disposable money can spend more on direct-to-consumer genetic testing, like genetic and nutrigenomics testing, which encourages regional growth. In addition, the arrival of significant industry players in the area and accelerated technology advancements will foster market expansion locally.
During the forecasted years, Asia Pacific is anticipated to experience significant growth. This is primarily due to improvements in awareness and diagnostic skills. Furthermore, this region will benefit financially from implementing frameworks and policies that support illness management. In China, only a relatively smaller percentage of the population uses genetic screening services, although demand is augmenting. With this, many foreign businesses are anticipated to enter the China direct-to-consumer genetic testing industry to offer affordable services.
Some of the major key players in the direct-to-consumer genetic testing market are 23andme Inc., 24Genetics, Ancestry.com LLC, Atlas Biomed, Color Genomics, DNAfit, Gene by Gene, Chengdu Twenty-Three Rubik’s Cube Biotechnology Co., Ltd., EasyDNA, Mapmygenome, MyHeritage Ltd., Laboratory Corporation of America Holdings, Myriad Genetics, Inc., Konica Minolta, Inc., XCODE Life.